DB:73C

Stock Analysis Report

Executive Summary

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company.


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Concert Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 73C's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-14.6%

73C

-0.7%

DE Biotechs

-0.6%

DE Market


1 Year Return

-39.9%

73C

-13.2%

DE Biotechs

-20.9%

DE Market

Return vs Industry: 73C underperformed the German Biotechs industry which returned -13.2% over the past year.

Return vs Market: 73C underperformed the German Market which returned -20.9% over the past year.


Shareholder returns

73CIndustryMarket
7 Day-14.6%-0.7%-0.6%
30 Day-15.2%-8.2%-18.6%
90 Day-14.6%-21.0%-26.2%
1 Year-39.9%-39.9%-12.9%-13.2%-18.6%-20.9%
3 Year-54.2%-54.2%14.5%13.2%-19.0%-25.8%
5 Year-50.3%-50.3%-9.5%-11.8%-21.2%-31.8%

Price Volatility Vs. Market

How volatile is Concert Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Concert Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 73C (€7) is trading below our estimate of fair value (€42.06)

Significantly Below Fair Value: 73C is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 73C is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 73C is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 73C's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 73C is good value based on its PB Ratio (1.9x) compared to the DE Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Concert Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

33.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 73C is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 73C is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 73C is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 73C's revenue (59.8% per year) is forecast to grow faster than the German market (3.9% per year).

High Growth Revenue: 73C's revenue (59.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 73C's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Concert Pharmaceuticals performed over the past 5 years?

-15.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 73C is currently unprofitable.

Growing Profit Margin: 73C is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 73C is unprofitable, and losses have increased over the past 5 years at a rate of -15.1% per year.

Accelerating Growth: Unable to compare 73C's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 73C is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).


Return on Equity

High ROE: 73C has a negative Return on Equity (-77.04%), as it is currently unprofitable.


Next Steps

Financial Health

How is Concert Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: 73C's short term assets ($116.9M) exceed its short term liabilities ($17.3M).

Long Term Liabilities: 73C's short term assets ($116.9M) exceed its long term liabilities ($18.7M).


Debt to Equity History and Analysis

Debt Level: 73C is debt free.

Reducing Debt: 73C has no debt compared to 5 years ago when its debt to equity ratio was 12.8%.


Balance Sheet

Inventory Level: 73C has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 73C's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 73C has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 73C has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -2.5% each year.


Next Steps

Dividend

What is Concert Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 73C's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 73C's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 73C's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 73C's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 73C's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Roger Tung (59yo)

14s

Tenure

US$4,607,848

Compensation

Dr. Roger D. Tung, Ph.D., Co-founded Concert Pharmaceuticals, Inc. in April 2006 and has been its Chief Executive Officer and President since April 2006. Dr. Tung worked in venture-backed start-up and majo ...


CEO Compensation Analysis

Compensation vs Market: Roger's total compensation ($USD4.61M) is above average for companies of similar size in the German market ($USD744.69K).

Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Richard Aldrich
Co-Founder & Chairman of the Board13.92yrsUS$205.61k1.3% $2.8m
Roger Tung
Co-Founder14yrsUS$4.61m2.71% $5.8m
Marc Becker
Chief Financial Officer2.25yrsUS$2.45mno data
Nancy Stuart
Chief Operating Officer12.5yrsUS$1.91m0.34% $735.4k
Justine Koenigsberg
Senior Vice President of Corporate Communications and Investor Relationsno datano datano data
Jeffrey Munsie
Chief Legal Officer & Corporate Secretary0.58yrno datano data
James Cassella
Chief Development Officer5.17yrsUS$1.96m0.072% $153.6k
Ian Silverman
Senior Legal Advisor2.83yrsUS$539.56kno data

4.0yrs

Average Tenure

61yo

Average Age

Experienced Management: 73C's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Richard Aldrich
Co-Founder & Chairman of the Board13.92yrsUS$205.61k1.3% $2.8m
Roger Tung
Co-Founder14yrsUS$4.61m2.71% $5.8m
Christine van Heek
Independent Director4yrsUS$181.25k0.034% $72.6k
Ronald Barrett
Independent Director12.33yrsUS$185.12kno data
Peter Hutt
Independent Director13.33yrsUS$181.32k0.015% $32.1k
Wilfred Jaeger
Independent Director13.92yrsUS$181.25kno data
Jesper Høiland
Director1yrno datano data
Thomas Auchincloss
Independent Director5.33yrsUS$188.75k0.022% $47.2k

12.8yrs

Average Tenure

62.5yo

Average Age

Experienced Board: 73C's board of directors are seasoned and experienced ( 12.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 73C insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Concert Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Concert Pharmaceuticals, Inc.
  • Ticker: 73C
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$230.492m
  • Listing Market Cap: US$213.643m
  • Shares outstanding: 29.44m
  • Website: https://www.concertpharma.com

Number of Employees


Location

  • Concert Pharmaceuticals, Inc.
  • 65 Hayden Avenue
  • Suite 3000N
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CNCENasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014
73CDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014
73CBRSE (Berne Stock Exchange)YesCommon StockCHCHFFeb 2014

Biography

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer’s disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/05 05:12
End of Day Share Price2020/04/03 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.